These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 30098515)

  • 1. Clinicopathologic features of 300 rhabdomyosarcomas with emphasis upon differential expression of skeletal muscle specific markers in the various subtypes: A single institutional experience.
    Rekhi B; Gupta C; Chinnaswamy G; Qureshi S; Vora T; Khanna N; Laskar S
    Ann Diagn Pathol; 2018 Oct; 36():50-60. PubMed ID: 30098515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
    Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
    Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma.
    Folpe AL; McKenney JK; Bridge JA; Weiss SW
    Am J Surg Pathol; 2002 Sep; 26(9):1175-83. PubMed ID: 12218574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience.
    Morotti RA; Nicol KK; Parham DM; Teot LA; Moore J; Hayes J; Meyer W; Qualman SJ;
    Am J Surg Pathol; 2006 Aug; 30(8):962-8. PubMed ID: 16861966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathological, immunohistochemical and molecular cytogenetic analysis of 21 spindle cell/sclerosing rhabdomyosarcomas.
    Rekhi B; Singhvi T
    APMIS; 2014 Nov; 122(11):1144-52. PubMed ID: 24730567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.
    Rekhi B; Upadhyay P; Ramteke MP; Dutt A
    Mod Pathol; 2016 Dec; 29(12):1532-1540. PubMed ID: 27562493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome.
    Owosho AA; Huang SC; Chen S; Kashikar S; Estilo CL; Wolden SL; Wexler LH; Huryn JM; Antonescu CR
    Oral Oncol; 2016 Oct; 61():89-97. PubMed ID: 27688110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
    Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
    Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expanding morphological and genetic spectrum of MYOD1-mutant spindle cell/sclerosing rhabdomyosarcomas: a clinicopathological and molecular comparison of mutated and non-mutated cases.
    Tsai JW; ChangChien YC; Lee JC; Kao YC; Li WS; Liang CW; Liao IC; Chang YM; Wang JC; Tsao CF; Yu SC; Huang HY
    Histopathology; 2019 May; 74(6):933-943. PubMed ID: 30604891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Myogenin and MyoD1 as Immunohistochemical Markers of Canine Rhabdomyosarcoma.
    Tuohy JL; Byer BJ; Royer S; Keller C; Nagai-Singer MA; Regan DP; Seguin B
    Vet Pathol; 2021 May; 58(3):516-526. PubMed ID: 33691532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rhabdomyosarcoma in middle to old-aged patients: analysis of clinicopathological features and prognosis in 76 cases].
    Yu L; Wang J
    Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):910-6. PubMed ID: 23336377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myogenin--a more specific target for RT-PCR detection of rhabdomyosarcoma than MyoD1.
    Michelagnoli MP; Burchill SA; Cullinane C; Selby PJ; Lewis IJ
    Med Pediatr Oncol; 2003 Jan; 40(1):1-8. PubMed ID: 12426678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomorphology of spindle cell/sclerosing rhabdomyosarcoma, including MYOD1 (LI22R) mutation result.
    Rekhi B; Dodd L; Dharavath B; Dutt A
    Diagn Cytopathol; 2022 Dec; 50(12):E367-E372. PubMed ID: 35929754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers.
    Furlong MA; Mentzel T; Fanburg-Smith JC
    Mod Pathol; 2001 Jun; 14(6):595-603. PubMed ID: 11406662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Spindle cell/sclerosing rhabdomyosarcoma: a clinicopathological study of 20 cases].
    Yang L; Zhang HJ; Yang SJ
    Zhonghua Bing Li Xue Za Zhi; 2020 Apr; 49(4):336-342. PubMed ID: 32268670
    [No Abstract]   [Full Text] [Related]  

  • 16. Rhabdomyosarcoma: molecular analysis of Igf2, MyoD1 and Myogenin expression.
    Krskova L; Augustinakova A; Drahokoupilova E; Sumerauer D; Mudry P; Kodet R
    Neoplasma; 2011; 58(5):415-23. PubMed ID: 21744995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood.
    Wang NP; Marx J; McNutt MA; Rutledge JC; Gown AM
    Am J Pathol; 1995 Dec; 147(6):1799-810. PubMed ID: 7495304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers.
    Sartori F; Alaggio R; Zanazzo G; Garaventa A; Di Cataldo A; Carli M; Rosolen A;
    Cancer; 2006 Apr; 106(8):1766-75. PubMed ID: 16544315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group.
    Chiles MC; Parham DM; Qualman SJ; Teot LA; Bridge JA; Ullrich F; Barr FG; Meyer WH;
    Pediatr Dev Pathol; 2004; 7(6):583-94. PubMed ID: 15630526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of New Monoclonal Anti-MyoD1 (MX049) for the Diagnosis of Rhabdomyosarcoma: Comparison with 5.8A, EP212, Anti-Desmin, Anti-Myogenin, and Fluorescence
    He Y; Chen X; Yu X
    Ann Clin Lab Sci; 2020 May; 50(3):412-416. PubMed ID: 32581037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.